|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 雌激素受体相关受体亚型在卵巢癌中的表达及其与预后的关系显示文摘目的探讨雌激素受体相关受体(ERRs)亚型α、β、γ在卵巢癌中的表达及其与预后的关系。方法激光共聚焦显微镜观察ERRα蛋白在卵巢癌细胞株SKOV3和OVCAR3细胞内的定位。RT-PCR技术检测33份卵巢癌组织以及12份正常卵巢组织中3种ERRs亚型的mRNA表达,并结合临床病理指标分析其预后情况。结果ERRα蛋白主要分布于SKOV3和OVCAR3细胞的细胞核内。卵巢癌组织中ERRαmRNA的阳性表达率(58%)和ERRγmRNA的阳性表达率(48%)显著高于正常卵巢组织(分别为17%和33%,P<0.05);ERRβmRNA的阳性表达率在卵巢癌组织和正常卵巢组织中都很低(分别为9%和0),两者比较,差异无统计学意义(P=0.795)。ERRαmRNA的阳性表达与卵巢癌的手术病理分期(r=0.639,P=0.017)、病理分级(r=0.520,P=0.022)呈正相关。ERRαmRNA阳性表达的卵巢癌患者,其中位数整体生存时间(19.0个月)明显短于ERRαmRNA阴性表达患者(31.5个月,P=0.015),但两者间的无瘤生存时间(分别为12.6和14.5个月)比较,差异无统计学意义(P=0.820);ERRγmRNA阳性表达患者的中位数无瘤生存时间(18.0个月)显著长于ERRγmRNA阴性表达患者(13.5个月,P=0.020),但两者间中位数整体生存时间(分别为23.4和19.6个月)比较,差异无统计学意义(P=0.093)。结论ERRα蛋白主要表达于卵巢癌细胞核内。ERRαmRNA高表达与卵巢癌患者的预后差有关,而ERRγmRNA高表达可能提示患者预后较好。 | 孙蓬明 魏丽惠 Jalid Sehouli Carsten Denkert 赵丹 高敏 孙秀丽 Werner Litchtenegger | 2005 | 中华妇产科杂志2005，40，8： | 6 |
| 2 | 孤儿核受体-雌激素受体相关受体α-1亚型在卵巢癌中表达的临床意义显示文摘目的:明确孤儿核受体-雌激素受体相关受体(Estrogen receptor-related receptors,ERRs)α-1亚型在卵巢癌组织中的表达情况及其临床意义。方法:采用实时荧光定量RT-PCR和免疫组化方法检测人ERRα-1在45例卵巢癌组织标本和15例正常卵巢组织中的mRNA和蛋白表达情况;采用ELISA方法分析各样本的血清CA125水平;随访指标为整体生存时间和无瘤生存时间。结果:免疫组化分析表明ERRα-1在卵巢癌组织中的表达率显著高于正常组织(P<0·05)。定量PCR分析表明卵巢癌组织中ERRα-1的mRNA平均表达丰度显著高于正常卵巢组织(P<0·05)。卵巢癌患者血清CA125水平分析显示ERRα-1阳性组CA125明显升高(P<0·05)。随访结果显示ERRα-1阳性的卵巢癌患者的整体生存时间比ERRα-1阴性患者明显减少(P<0·05),但两组无瘤生存时间并无差异(P>0·05)。结论:ERRα-1可能在卵巢癌的发生发展中起重要作用,ERRα-1表达增加与卵巢癌的预后不良有关。 | 孙蓬明 魏丽惠 王建六 袁淑惠 宋一一 Jalid Sehouli | 2008 | 中国妇幼保健2008，23，17： | 2 |
| 3 | A prospective multicenter study of treosulfan in elderly patients with recurrent ovarian cancer: results of a planned safety analysis显示文摘 | Sven Mahner Gülten Oskay-?zcelik Elke Heidrich-Lorsbach Stefan Fuxius Harald Sommer Peter Klare Antje Belau Birgit Ruhmland Thomas Heuser Heinz K?lbl Susanne Markmann Jalid Sehouli | 2012 | Journal of Cancer Research and Clinical Oncology2012，，8： | 1 |
| 4 | Systematic analysis and validation of differential gene expression in ovarian serous adenocarcinomas and normal ovary显示文摘 | Dirk Bauerschlag Karen Br?utigam Roland Moll Jalid Sehouli Alexander Mustea Darius Salehin Maryla Krajewska John C. Reed Nicolai Maass Garret M. Hampton Ivo Meinhold-Heerlein | 2013 | Journal of Cancer Research and Clinical Oncology2013，，2： | 1 |
| 5 | Expression of estrogen receptor-related receptors, a subfamily of orphan nuclear receptors, as new tumor biomarkers in ovarian cancer cells显示文摘 | Pengming Sun Jalid Sehouli Carsten Denkert Alexander Mustea Dominique K?nsgen Ines Koch Lihui Wei Werner Lichtenegger | 2005 | Journal of Molecular Medicine2005，，6： | 1 |
| 6 | BAMBI is overexpressed in ovarian cancer and co-translocates with Smads into the nucleus upon TGF-? treatment显示文摘 | Dietmar Pils Michael Wittinger Michaela Petz Alfred Gugerell Wolfgang Gregor Angela Alfanz Reinhard Horvat Elena-Ioana Braicu Jalid Sehouli Robert Zeillinger Wolfgang Mikulits Michael Krainer | 2010 | Gynecologic Oncology2010，，2： | 1 |
| 7 | Expression of estrogen receptor-related receptors, a subfamily of orphan nuclear receptors,as new tumor biomarkers in ovarian cancer cells 显示文摘 | Pengming S Jalid S Carsten D | 2005 | Journal of Molecular Medicine2005，83，4： | 1 |
| 8 | Systematic pelvic and aortic lymphadenectomy in intermediate and high-risk endometrial cancer: Lymph-node mapping and identification of predictive factors for lymph-node status显示文摘 | Christina Fotopoulou Konstantinos Savvatis Robert Kraetschell Joerg C. Schefold Werner Lichtenegger Jalid Sehouli | 2009 | European Journal of Obstetrics and Gynecology2009，，2： | 1 |
| 9 | Primary Radical Surgery in Elderly Patients With Epithelial Ovarian Cancer: Analysis of Surgical Outcome and Long-Term Survival显示文摘 | Christina Fotopoulou Konstantinos Savvatis Elisabeth Steinhagen-Thiessen Marcus Bahra Werner Lichtenegger Jalid Sehouli | 2010 | International Journal of Gynecological Cancer2010，，： | 1 |
| 10 | Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase Ⅲ study of the north-eastern german society of gynecological oncoiogy ovarian cancer study group显示文摘 | Jalid SD Stengel Guelten OO | 2008 | Clin Oncol2008，26，7： | 1 |
| 11 | Alkali metal emission during pyrolysis of biomass显示文摘 | OLSSON J G JALID U PETTERSSON B C | 1997 | Energy Fuels1997，11，4： | 1 |
| 12 | Pseudo-or real progression? An ovarian cancer patient under nivolumab:A case report显示文摘BACKGROUND Checkpoint-Inhibition has revolutionized the treatment for several entities such as melanoma and renal cell carcinoma.The first encouraging experience in ovarian cancer was reported for nivolumab,a fully humanized anti-programmed death-1 antibody.Pseudoprogression is a new phenomenon associated with these novel immuno-oncologic agents.It can be explained by infiltrating leucocytes and edema that result in a temporary increase in tumor size and delayed subsequent shrinkage due to tumor cell destruction.CASE SUMMARY We report on a 47-year old patient with platinum-resistant ovarian cancer that was treated off-label with nivolumab 3mg/kg iv d1q14d.She first experienced classic pseudoprogression with inguinal lymph node swelling after cycle two and subsequent shrinkage.After 6 cycles she presented with rectal bleeding and progressive disease was diagnosed due to new tumor infiltration into the rectum.CONCLUSION Clinicians should be aware of pseudoprogression,its underlying mechanisms and strategies to discriminate pseudo-from real progression in ovarian cancer. | Mona Passler Eliane T Taube Jalid Sehouli Klaus Pietzner | 2019 | World Journal of Clinical Oncology2019，10，7： | 0 |
| 13 | Molecular targeted therapy of gynecological malignanttumors: the development and challenge, from laboratory toclinic显示文摘More and more molecular drugs based on targeted therapy have been utilized in the treatment of gynecologic cancer,especially in ovarian cancer.In this article,we systematically review the current targeted therapeutic trials running in clinic.Large,randomized trials have been conducted in the treatment of ovarian cancer,endometrial cancer and cervical cancer by using small molecule,antisense,mutational gene as well as antibodies.Other planned or ongoing trials currently targeted at molecular markers which may play important roles in gynecological carcinogenesis and progression suggest that combination chemotherapy with molecular targeted therapy will ultimately be an important option. | Pengming SUN Jalid SEHOULI Lihui WEI | 2009 | Frontiers of Medicine2009，3，3： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员